Skip to main content

Fiscal Wizard · Single-issue tearsheet

ACTU / Jun 21, 2026 Run #7355

ACTU

Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Composite verdict

F 11.8 / 100
Bearish setup · Reversal 9 drivers · 6 gates blocking
  • MA Rejection
  • Double 7s
  • TRIX Zero-Line
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 415th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Bearish 8Mean-reversion Neutral 43

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

23.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Return on Capital Employed 0
Return on Assets 0
Free Cash Flow Yield 0

Technicals Bearish

0.1 / 100

Bearish setup leads (MA Rejection, Double 7s, TRIX Zero-Line); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
MA Rejection 20
Aroon Oscillator 22
TRIX Zero-Line 22

Risk Gates

6 blocking 1 caution

6 guards active, 24 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ACTU.